El f\u00e0rmac Denosumab s’utilitza actualment per al tractament de l’osteoporosi i la met\u00e0stasi a l’os. Des de fa m\u00e9s d’una d\u00e8cada, tamb\u00e9 se n’estudia el potencial benefici terap\u00e8utic en el tractament del c\u00e0ncer de mama. No obstant aix\u00f2, amb dades cl\u00edniques contradict\u00f2ries, el benefici en la superviv\u00e8ncia de pacients amb c\u00e0ncer de mama no \u00e9s clar.<\/p>\n
Amb l’objectiu de seleccionar les pacients que es podrien beneficiar d’aquest f\u00e0rmac, els investigadors del Centre Nacional d’Investigacions Oncol\u00f2giques (CNIO) i l’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL), liderats per Eva Gonz\u00e1lez-Su\u00e1rez, han analitzat l’expressi\u00f3 de la prote\u00efna RANK i del seu lligand RANKL en m\u00e9s de 2.000 tumors de mama<\/strong>, 777 sense expressi\u00f3 de receptors hormonals, procedents de quatre cohorts independents.<\/p>\n Els resultats mostren que l’expressi\u00f3 de la prote\u00efna RANK \u00e9s m\u00e9s freq\u00fcent en els tumors sense receptors hormonals, on s’associa amb un mal pron\u00f2stic i una mala resposta a la quimioter\u00e0pia. A m\u00e9s, els investigadors van observar una activaci\u00f3 m\u00e9s gran de la via de RANK en els tumors de mama despr\u00e9s de la menopausa, amb la qual cosa, l’\u00fas de l’inhibidor Denosumab, afegit al tractament de base, podria tenir m\u00e9s valor terap\u00e8utic en pacients postmenop\u00e0usiques amb tumors de mama hormononegatius i expressi\u00f3 de la prote\u00efna RANK<\/strong>.<\/p>\n Els tumors sense receptors hormonals, aquells en qu\u00e8 les c\u00e8l\u00b7lules canceroses no contenen receptors d’estrogen i progesterona, tenen pitjor pron\u00f2stic i opcions de tractament limitades. “Atesa l’heterogene\u00eftat del grup de tumors de mama hormono negatius, comptar amb biomarcadors que discriminin millor el pron\u00f2stic d’aquests pacients \u00e9s essencial, i m\u00e9s si aquests marcadors permeten triar el tractament m\u00e9s adequat<\/em>“, assenyala Eva Gonz\u00e1lez-Su\u00e1rez<\/strong>, cap del Grup de Transformaci\u00f3 i met\u00e0stasi del CNIO i investigadora de l’IDIBELL. El seg\u00fcent pas seria, per tant, “dissenyar un assaig cl\u00ednic en pacients amb tumors hormono negatius, que expressin el receptor RANK en pre i postmenopausa<\/em>“.<\/p>\n <\/p>\n <\/p>\n En aquest estudi, Marina Ciscar<\/strong> i Eva M. Trinidad<\/strong>, co-primeres autores de l’estudi, van unir esfor\u00e7os per determinar el valor terap\u00e8utic de la via RANK en c\u00e0ncer de mama. Ciscar i altres membres de l’equip de Gonz\u00e1lez-Su\u00e1rez, van analitzar aquestes prote\u00efnes en m\u00e9s de 2000 mostres de tumors de mama de quatre cohorts antigues, la majoria provinents de l’equip d’Emad Rakha, a la Universitat de Nottingham, on segueixen les pacients des de fa dues d\u00e8cades, i dues d’espanyoles, de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i del CNIO.<\/p>\n Ciscar<\/strong> i els seus col\u00b7laboradors van trobar que al 40% dels tumors hormono negatius s’expressava el receptor RANK, i aquesta expressi\u00f3 s’associava a pitjor pron\u00f2stic i superviv\u00e8ncia de les pacients.<\/p>\n Per la seva banda, Eva M. Trinidad<\/strong> va emprar models experimentals de ratol\u00ed als quals va implantar un petit fragment dels tumors humans al mateix \u00f2rgan d’origen. En aquests models, la inhibici\u00f3 de RANKL va reduir la proliferaci\u00f3 i plasticitat de les c\u00e8l\u00b7lules tumorals humanes, va regular la immunitat i el metabolisme del tumor i va millorar la resposta a la quimioter\u00e0pia. D’aquesta manera, els investigadors van concloure que la via de RANK podria servir com a biomarcador i tamb\u00e9 com a diana terap\u00e8utica.<\/p>\n <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" “Aquests resultats reactiven l’opci\u00f3 d’obrir assajos cl\u00ednics amb Denosumab en c\u00e0ncer de mama seleccionant els pacients”, diu Eva Gonz\u00e1lez-Su\u00e1rez, autora principal i investigadora del CNIO i l’IDIBELL.<\/p>\n","protected":false},"author":8,"featured_media":23161,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,371],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 12:13:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23149"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=23149"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23149\/revisions"}],"predecessor-version":[{"id":23150,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23149\/revisions\/23150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/23161"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=23149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=23149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=23149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}M\u00e9s de 2000 mostres de quatre cohorts<\/h3>\n